Dren Bio Logo
dren's logo

Robust depletion of disease-causing cells and agents

Dren’s team has profound expertise in antibody executed elimination of pathological cells


We selectively engage an effector cell for targeted depletion of diseased cells or agents

The company’s pipeline has two lead programs:

dren's targetDR-01 utilizes antibody-mediated killing of a cell type involved in leukemia, lymphomas and autoimmune diseases


  • dren's targetInitially targeting neglected HemOnc indications with no approved therapies

  • dren's targetExpansion into defined subsets of autoimmune diseases

monocyte cell

dren's targetDR-02 is an enhanced antibody-based platform for depletion of cells and disease-inducing agents through a novel MOA


  • dren's targetPotential applications in solid tumors, hematologic neoplasms, infectious diseases and protein aggregate diseases

  • dren's targetA proprietary monotherapy with multiple modes of action

    • dren's targetDirect depletion
    • dren's targetImmune stimulation
    • dren's targetTarget engagement
    • dren's targetAntigen presentation

Leadership

Board of Directors and Investors

Alexandria Venture Investments

Scientific Advisory Board

Careers

Corporate Controller


About the Company:

Dren Bio (the “Company”) is a privately held, pre-clinical stage biopharmaceutical company focused on developing therapeutic antibodies for the treatment of cancer, autoimmune and other serious diseases. The Company’s management team and scientific advisors have profound expertise covering the discovery and development of engineered antibodies designed to selectively target and deplete pathological cells. Dren Bio’s pipeline is currently comprised of two distinct programs. The first program surrounds DR-01, the Company’s lead product candidate, which induces antibody-mediated killing of a cell type that is responsible for a multitude of hematologic malignancies and plays a key role in various autoimmune diseases. The Company’s second program is a proprietary antibody-based technology platform, its Targeted Myeloid Engager, which utilizes a novel mechanism of action to selectively engage myeloid cells for the targeted depletion of diseased cells and disease-inducing agents, as well as to induce immunostimulation.

Function:

Finance

Level:

Sr. Director / Vice President

Location:

Redwood City, CA

Reporting Manager:

SVP, Finance

About the Opportunity:

Dren Bio is seeking a highly motivated and experienced Corporate Controller to lead its accounting department in a fast-growing, lean environment. Reporting to the SVP of Finance, the Controller will primarily be responsible for all aspects of the financial accounting and reporting, procurement, treasury, and tax functions. This role will also initially include certain aspects of FP&A, Legal (corporate governance) and HR functions.

The ideal candidate will have had previous experience at a pre-IPO life sciences company, preferably in the biotechnology or pharmaceutical industries. The candidate should be well versed in developing and maintaining accounting policies, practices, and procedures, and have a long track record of managing teams to ensure work is properly allocated and completed in a timely and accurate manner. As part of the Dren’s anticipated growth, the Corporate Controller will be expected to hire, supervise and mentor a team, address tight deadlines on a multitude of accounting activities including general ledger preparation, financial statements, year-end audit preparation, and the support of ongoing budget and forecast activities. To succeed in this role, the candidate must be self-directed and a possess a thorough knowledge of core accounting principles and procedures.

While Dren is currently small, the company is actively planning for success and expects the Corporate Controller to be a key member of the management team, with ample opportunities for growth both upwards and across the company.

Role and Responsibilities:
  • Oversees the hiring and supervision of accounting and related personnel.

  • Develop effective working relationships with leaders throughout the organization to ensure strong partnership between finance and the business.

  • Support readiness for future financings, including a potential IPO by providing support in the drafting and reviewing of financing documents.

  • Oversee general accounting, ledgers, reporting systems, payroll, 401K, accounts payable and treasury functions.

  • Oversee all aspects of timely and accurate quarterly and annual close processes, including clinical trial and manufacturing accruals, preparation of journal entries and account reconciliations.

  • Prepare monthly and quarterly internal management reporting package, including preparing variance and fluctuation analysis.

  • Ensure strong accounting and operational processes to drive operational performance.

  • Implement, document and maintain adequate and effective internal controls and processes to ensure timely and accurate financial reporting, including narrative standard operating procedure documentation and communication thereof with employees.

  • Supervise outsourced procurement, accounts payable, and payroll service providers for all operational functions.

  • Handles day-to-day cash management and oversight.

  • Own the company’s capitalization table and stock administration processes, including stock option issuances, grant processing and reporting, employee communication on stock related matters, facilitation of 409A common stock valuation reports, etc.

  • Own the company’s tax reporting and filing processes, including management and review of files prepared by the Company’s tax providers for the Company’s income tax returns, tax provision, tax disclosures, tax studies and analyses.

  • Complete DE Franchise tax, property tax, use tax, payroll tax, and other local tax and business license filings.

  • Coordinate requirements and renewal of various insurance plans, including directors & officers, clinical trial, property, and general liability.

  • Manage audit processes and relationships with external auditors and financial reporting consultants. Support the conduct of all external audit activity.

  • Serve as the company’s expert for technical accounting matters, keeping abreast of changes in accounting requirements; Develop, maintain, and enforce technical accounting policies and procedures in accordance with US GAAP via oversight of technical accounting projects related to new and proposed accounting standards and complex accounting transactions (license agreements, collaboration agreements, leases, material R&D contracts, etc.).

  • Together with the SVP of Finance and IT, manage and enhance the company’s ERP, business, and accounting systems.

  • Assists with ensuring completeness of corporate governance and data management (such as BOD minutes and written consents, stockholder consents, board approvals, transaction documentation, executed agreements, etc.).

  • Complete investor requests, including confirmation letters.

  • Partner with the SVP of Finance and other executive management team in preparing Board presentations.

Education, Experience and Qualification Requirements:
  • Bachelors’ degree in accounting or related discipline with approximately 10+ years’ progressive accounting and finance experience, including 5+ years’ experience at a life science company.

  • Big 4 audit experience and CPA strongly preferred.

  • IPO experience required.

  • SOX 404 experience preferred.

Core Competencies, Knowledge and Skill Requirements:
  • Strong understanding of both AICPA and PCAOB standards, including current accounting pronouncements relevant to a pre-IPO life sciences company.

  • Strong technical accounting experience, including writing accounting memos and negotiating complex accounting issues with external auditors.

  • Ability to proactively identify accounting issues and initiative to solve challenges.

  • Experienced with common life science accounting focal areas including clinical trial and manufacturing accruals.

  • Solid foundation in SEC rules and regulations, SEC reporting (including 10-K, 10-Q, proxy and 8-Ks).

  • Expert level knowledge and proficiency with Excel, NetSuite and Bill.com. Experience with Prendio, Tallie, and Blackline a plus.

  • Technically savvy with systems and ability to improve processes and utilize technology to enhance productivity, reduce errors, and mitigate risks.

  • Ability to proactively manage tasks and workloads while being flexible, i.e. able to adapt/adjust with short notice.

  • Excellent management and supervisory skills.

  • Strong interpersonal skills and the ability to communicate effectively across a diverse range of departments and levels, including executive management. Ability to maintain positive, professional relationships with personnel at all levels of the organization.

  • Experience working with senior level management, exercising professionalism & discretion.

  • Ability to thrive in a fast-paced environment and to collaborate with cross-functional team members.

  • Excellent communication and presentation skills.

Salaries, Benefits and Other Employee Perks:

Dren Bio strongly believes in investing in, and rewarding, its employees. This philosophy is embodied in the Company’s total rewards program, which includes competitive cash compensation, equity incentive awards, and employer sponsored benefit offerings. Exact cash and equity compensation shall be commensurate with candidate’s experience and qualifications.

Employment Practices:

Dren Bio is an equal opportunity employer. Employment decisions are based on merit and business needs. Dren Bio will not discriminate against any job applicant because of race, color, national origin, ancestry, gender, sexual orientation, age, religion, creed, physical or mental disability, gender identity, medical condition, pregnancy, marital status, veteran status, or any other characteristic protected by federal, state or local law.

Interested Applicants:

Please send resume and cover letter to careers@drenbio.com

PDF Version

Scientist, Immunology


About the Company:

Dren Bio (the “Company”) is a privately held, pre-clinical stage biopharmaceutical company focused on developing therapeutic antibodies for the treatment of cancer, autoimmune and other serious diseases. The Company’s management team and scientific advisors have profound expertise covering the discovery and development of engineered antibodies designed to selectively target and deplete pathological cells. Dren Bio’s pipeline is currently comprised of two distinct programs. The first program surrounds DR-01, the Company’s lead product candidate, which induces antibody-mediated killing of a cell type that is responsible for a multitude of hematologic malignancies and plays a key role in various autoimmune diseases. The Company’s second program is a proprietary antibody-based technology platform, its Targeted Myeloid Engager, which utilizes a novel mechanism of action to selectively engage myeloid cells for the targeted depletion of diseased cells and disease-inducing agents, as well as to induce immunostimulation.

Function:

Immunology

Level:

Scientist

Location:

Redwood City, CA

Reporting Manager:

Senior Scientist I, Immunology

About the Opportunity:

Dren Bio is seeking a highly talented and motivated scientist to support our Targeted Myeloid Engager platform for the treatment of solid and hematological cancers. The ideal candidate is an expert in macrophage and/or dendritic cell biology with strong technical experience in probing how myeloid cells contribute to disease pathogenesis or could be restored to treat cancer and inflammatory disease. The candidate will work with a cross-functional team of scientists (immunologists, cell biologists, biochemists, and protein engineers) to advance research stage programs into early clinical development. The candidate will be expected to perform essential ex vivo and in vivo studies to not only assess efficacy of our novel therapeutic agents but to elucidate their impact on macrophage and dendritic cell functions in the tumor microenvironment. Importantly, the successful candidate will be provided necessary training, support, and opportunities to grow into and lead a therapeutic program or project sub-teams, and mentor other researchers.

Role and Responsibilities:
  • Work collaboratively with other researchers to advance various therapeutic antibodies in different cancer types

  • Design, conduct, and interpret high quality ex vivo studies (e.g. ADCC, ADCP, cytokine profiling, gene expression profiling) and in vivo studies (e.g. syngeneic, xenograft, and/or humanized mouse models of cancer) to evaluate efficacy and mechanism of action (MOA) of Dren Bio’s novel therapeutic agents

  • Specific tasks include animal or human tissue processing, multi-color flow cytometry for immuno-phenotyping, cytokine profiling by MSD or Luminex, ADCC or ADCP assays using Incucyte live-cell imaging and flow cytometry, IHC/IF and confocal microscopy, DNA/RNA extraction for gene expression studies, various biochemical techniques (IP, western blot, IHC, and IF)

  • Develop and execute assays to evaluate antigen presentation by macrophages and dendritic cells, and T cell activation

  • Well-versed in various data processing and analysis software (e.g. FlowJo, Prism, ImageJ)

  • Mentor and train other scientists on novel tools and techniques

  • Become a project leader for a specific therapeutic program, while demonstrating flexibility and enthusiasm to support evolving company goals that are inherent of a fast-paced start-up environment

  • Meticulous record-keeping of scientific data, methods, and study designs

  • Present data in various forums, including lab meetings, department meetings, and multi-functional project teams

  • Publish scientific and methodological results in high quality journals

Education, Experience and Qualification Requirements:
  • PhD in Immunology, Cancer Biology, Biochemistry, or related discipline with approximately 0-3+ years of experience in academia or biopharmaceutical industry.

Core Competencies, Knowledge and Skill Requirements:
  • The candidate is expected to have in-depth training in immunology and rich technical expertise in cellular and molecular immunology

  • Routine literature search and keeping up to date of the competitive landscape of immuno-oncology

  • Strong expertise in animal or human tissue processing and downstream assays (i.e. immuno-phenotyping by multi-color flow cytometry, immunohistochemistry, cell-based functional assays, biochemical assays)

  • Hands-on experience in designing and executing in vivo studies (e.g. syngeneic, xenograft, PDX, humanized mouse models of immuno-oncology)

  • Proficiency in IP, IV, SC and PO dosing, blood and tissue collection are required

  • Experience with primary cell isolation and culture

  • Must have a record of successful scientific accomplishments as evidenced by one or more first-author papers published or accepted in a well-recognized and peer-reviewed journals

  • Strong analytical and critical thinking skills with the ability to interpret complex data and highly motivated to learn and support the drug development efforts

  • Motivated self-starter who can work independently and collaboratively in a dynamic team environment with a proactive attitude

  • Excellent written and verbal communication skills

  • Ability to work in a fast-paced environment and the flexibility to align daily work with project needs

  • Ability to set goals and prioritize tasks and resources to achieve superior work quality and efficiency

  • Must be well organized, have a strong work ethic, attention to detail and be diligent in data documentation

Salaries, Benefits and Other Employee Perks:

Dren Bio strongly believes in investing in, and rewarding, its employees. This philosophy is embodied in the Company’s total rewards program, which includes competitive cash compensation, equity incentive awards, and employer sponsored benefit offerings. Exact cash and equity compensation shall be commensurate with candidate’s experience and qualifications.

Employment Practices:

Dren Bio is an equal opportunity employer. Employment decisions are based on merit and business needs. Dren Bio will not discriminate against any job applicant because of race, color, national origin, ancestry, gender, sexual orientation, age, religion, creed, physical or mental disability, gender identity, medical condition, pregnancy, marital status, veteran status, or any other characteristic protected by federal, state or local law.

Interested Applicants:

Please send resume and cover letter to research_careers@drenbio.com.

PDF Version

News

Dren Bio announces a $60M Series A financing

2020-10-16

SAN CARLOS, CA,


Dren Bio, Inc., a company developing powerful protein-engineering technologies for depletion of cells, protein aggregates and other disease-causing agents, announced the closing of a $60 million Series A investment round. The round was led by SR One and Taiho Ventures, LLC , with participation from existing investors 8VC and Mission BioCapital and new investors including BVF Partners L.P., HBM Healthcare Investments, and Alexandria Venture Investments.

Dren will utilize the proceeds to advance its two lead programs through early clinical development. Dren’s first program, DR-01, is an antibody-based therapy to treat rare leukemias and lymphomas as well as specific phenotypes of auto-immune disorders. Dren’s second program, DR-02, is an enhanced antibody-based platform to deplete cells and other disease-causing agents through a novel mechanism-of-action.

"Our strategy is to select the appropriate immune cell type to induce potent and measurable therapeutic effects," said Nenad Tomasevic, PhD, Dren’s Chief Executive Officer and co-founder. "The DR-01 program employs enhanced ADCC to eliminate pathologic cells in clearly defined patient populations. Our DR-02 platform engages a different immune effector cell to a target, resulting in immune stimulation and target depletion."

Dr. Tomasevic brings over twenty years of biotech development experience and previously co-founded Allakos, a clinical-stage, publicly-traded company nearing commercialization.

Lewis Lanier, PhD, Chair of Dren’s Scientific Advisory Board, said, "Dren’s therapies are exciting because they offer novel strategeies to meet an unmet need in treatment of lymphomas and leukemias and to potentially enhance the potency of T cells in cancer immunotherapy." Dr. Lanier is the Chair of Microbiology and Immunology and the J. Michael Bishop MD Distinguished Professor at UCSF.

"We are impressed by Dren’s progress since the company’s inception in 2019," commented Rajeev Dadoo, Partner at SR One. "The DR-01 program has a clear development path to the clinic, focusing on diseases with no approved therapies."

"In oncology, the DR-02 platform could enable direct and selective depletion of cancer cells accompanied by localized immune stimulation," said Sakae Asanuma, President at Taiho Ventures. "The technology is also demonstrating the potential to eliminate agents in diverse diseases, including infections and protein aggregation. We are proud to recognize Dren’s potential at an early stage and support its success."

Dren previously closed a $6 million Seed Financing in 2019 led by 8VC with participation by Mission BioCapital and prominent industry veterans. "We appreciate the support from Dren’s investors,who to date have committed over $66 million in funding for our programs," said John Wesley, co-founder and Chief Financial Officer. "The goal of our Series A financing is to bring two drug candidates to the clinic."

About Dren Bio:

Dren Bio is a San Carlos, CA based biotechnology company developing powerful protein engineering technologies to deplete cells, protein aggregates and other disease-causing agents. Dren’s lead programs are initially focused on hematologic neoplasms and solid cancers. Dren is actively working in other areas including auto-immune disorders and diseases of protein aggregation. Dren’s team includes accomplished research and development personnel with strong collective industry experience. For more information, please visit: https://drenbio.com/.

About SR One

SR One invests globally in emerging life science companies pursuing innovative science to significantly impact medical care. SR One’s team of investment professionals, located in the US and UK, have experience spanning basic science, drug development and commercialization. For more information, please visit: http://www.srone.com/

About Taiho Ventures

Taiho Ventures, LLC is the strategic corporate venture capital arm of Taiho Pharmaceutical Co., Ltd., a Japanese specialty pharma focusing on oncology, allergy and immunology, and urology. Taiho Ventures is looking at early-stage preclinical oncology companies as well as platform technology companies for our core therapeutic areas. Taiho Ventures will review the wide variety of modalities for both biologics and small molecules and also consider the option type of investments and spin-outs, in addition to the pure equity investments. For more information, please visit: https://www.taihoventures.com/

About 8VC

8VC is a leading technology investment firm investing in visionary teams and backing industry-transforming companies. The partners have a proven track-record as founders, engineers, and operators of successful companies including Palantir, Addepar, Affinity and OpenGov, among others. The predecessor firm Formation 8 was founded in 2012 and today, manages $1.1 billion in committed capital. 8VC was founded in 2016 and manages $2.4 billion in committed capital. 8VC invests primarily in SaaS companies and biotechnology. For more information, please visit http://8vc.com.

About BVF Partners L.P.

BVF Partners L.P. is a San Francisco-based investment management firm with more than 26 years investing in public and private biotechnology companies. For more information, please visit: https://www.bvflp.com/

About HBM Healthcare Investments

HBM Healthcare Investments holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN). For more information, please visit: https://www.hbmhealthcare.com/

About Mission BioCapital

Mission BioCapital (MBC) brings together the teams of Mission Bay Capital and BioInnovation Capital into a single venture firm. MBC is focused on making pivotal, early-stage investments in life science companies. We support entrepreneurs through a unique combination of shared lab spaces, capital investment and access to strategic partners. https://www.missionbiocapital.com/

About Alexandria Venture Investments

Alexandria Venture Investments, founded in 1996, is the strategic venture capital platform of Alexandria Real Estate Equities, Inc. (NYSE:ARE). With more than $1B under management, Alexandria Venture Investments has been recognized by Silicon Valley Bank as the #1 most active investor in biopharma by new deal volume since 2017. Alexandria Venture Investments provides long-term strategic investment capital to transformative seed-, early- and growth-stage life science, technology and agtech companies advancing innovative platforms to improve human health. For more information, please visit www.are.com/venture-investments.html.

CONTACT: Nalin Sar

Dren Bio, Inc.

nsar@drenbio.com

info@drenbio.com

PDF Version

Contact

Map of California

Address

400 Seaport Ct, Ste 102, Redwood City, CA 94063


Email Address

info@drenbio.com